Pannu, Jaspreet <br/><br/>
Smad1 pathway is activated in systemic sclerosis fibroblasts and is targeted by imatinib mesylate.  [electronic resource] 

 -  Arthritis and rheumatism  Aug 2008 
 - 2528-37 p.  digital 
<br/><br/> Publication Type: Journal Article; Research Support, N.I.H., Extramural; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>0004-3591 
<br/><br/><label>Standard No.: </label>10.1002/art.23698  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Benzamides<br/>Biopsy<br/>Case-Control Studies<br/>Cells, Cultured<br/>Connective Tissue Growth Factor<br/>Female<br/>Fibroblasts--drug effects<br/>Humans<br/>Imatinib Mesylate<br/>Immediate-Early Proteins--metabolism<br/>Intercellular Signaling Peptides and Proteins--metabolism<br/>Male<br/>Middle Aged<br/>Mitogen-Activated Protein Kinase 1--metabolism<br/>Mitogen-Activated Protein Kinase 3--metabolism<br/>Piperazines--pharmacology<br/>Protein Kinase Inhibitors--pharmacology<br/>Pyrimidines--pharmacology<br/>Scleroderma, Systemic--drug therapy<br/>Signal Transduction--drug effects<br/>Skin--drug effects<br/>Smad1 Protein--drug effects<br/>Transforming Growth Factor beta--metabolism